---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-065703"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T09:07:25.232756+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tenaya Therapeutics reports Q1 net loss of $26.9M; cash runway into H2 2026

## Summary
- Q1 2025 net loss $26.9M ($0.24 loss per share) vs $32.2M ($0.40 loss) in Q1 2024.
- Cash, equivalents and investments $88.2M at March 31; March public offering netted $48.8M, extending runway into H2 2026.
- TN-201 low-dose cohort showed improved NYHA class in all 3 patients and hypertrophy improvement in 2 of 3; Cohort 2 enrollment on track.
- TN-401 RIDGE-1 Phase 1b enrollment on track for H1 2025; initial data expected H2 2025.
- Restructuring with workforce reduction estimated at $1.6-$2.7M charges to extend cash runway.

## SEC filing metadata
- accession: 0000950170-25-065703
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000095017025065703/0000950170-25-065703-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000095017025065703/tnya-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-065703
- JSON: https://secwatch.observer/filing/0000950170-25-065703.json
- Plain text: https://secwatch.observer/filing/0000950170-25-065703.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.